EcoDrugPlus

Proteasome 20s Subunit Alpha 2a

Ensembl ID : ENSEEEG00000004213
Gene Symbol: PSMA2A
4 Cross references
260 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSEEEG00000019468
Gene Symbol: PSMA3
4 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSEEEG00000017962
Gene Symbol: PSMA4
4 Cross references
199 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSEEEG00000009714
Gene Symbol: PSMA5
4 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Alpha 6a

Ensembl ID : ENSEEEG00000013266
Gene Symbol: PSMA6A
4 Cross references
229 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSEEEG00000009391
Gene Symbol: PSMA8
4 Cross references
184 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSEEEG00000008988
Gene Symbol: PSMB1
4 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSEEEG00000003291
Gene Symbol: PSMB10
4 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSEEEG00000003364
Gene Symbol: PSMB11B
1 Cross references
161 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSEEEG00000007564
Gene Symbol: PSMB2
4 Cross references
222 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSEEEG00000018300
Gene Symbol: PSMB3
4 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSEEEG00000014026
Gene Symbol: PSMB4
4 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).